Serum creatine kinase isoenzymes in children with osteogenesis imperfecta
- 25 August 2016
- journal article
- clinical trial
- Published by Springer Nature in Osteoporosis International
- Vol. 28 (1) , 339-346
Abstract
This study evaluates serum creatine kinase isoenzyme activity in children with osteogenesis imperfecta to determine its usefulness as a biochemical marker during treatment with bisphosphonate. The changes of creatine kinase (CK) isoenzyme activity during and after discontinuation therapy were observed. These results could be useful in addressing over-treatment risk prevention. The brain isoenzyme of creatine kinase (CKbb) is highly expressed in mature osteoclasts during osteoclastogenesis, thus plays an important role in bone resorption. We previously identified high serum CKbb levels in 18 children with osteogenesis imperfect (OI) type 1 treated for 1 year with bisphosphonate (neridronate). In the present study, serum CK isoenzymes were evaluated in the same children with continuous versus discontinued neridronate treatment over a further 2-year follow-up period. This study included 18 children with OI type 1, 12 with continued (group A) and 6 with ceased (group B) neridronate treatment. Auxological data, serum biochemical markers of bone metabolism, bone mineral density z-score, and serum total CK and isoenzyme activities were determined in both groups. Serum CKbb was progressively and significantly increased in group A (p < 0.004) but rapidly decreased to undetectable levels in group B. In both groups, the cardiac muscle creatine kinase isoenzyme (CKmb) showed a marked decrease, while serum C-terminal telopeptide (CTx) levels were almost unchanged. This study provides evidence of the cumulative effect of neridronate administration in increasing serum CKbb levels and the reversible effect after its discontinuation. This approach could be employed for verifying the usefulness of serum CKbb as a biochemical marker in patients receiving prolonged bisphosphonate treatment. Moreover, the decreased serum CKmb levels suggest a systemic effect of these drugs.Keywords
This publication has 28 references indexed in Scilit:
- Revised Reference Curves for Bone Mineral Content and Areal Bone Mineral Density According to Age and Sex for Black and Non-Black Children: Results of the Bone Mineral Density in Childhood StudyThe Journal of Clinical Endocrinology & Metabolism, 2011
- The creatine kinase system and pleiotropic effects of creatineAmino Acids, 2011
- RANKL Up-regulates Brain-type Creatine Kinase via Poly(ADP-ribose) Polymerase-1 during OsteoclastogenesisJournal of Biological Chemistry, 2010
- Bisphosphonate-Induced Osteopetrosis: Novel Bone Modeling Defects, Metaphyseal Osteopenia, and Osteosclerosis Fractures After Drug Exposure CeasesJournal of Bone and Mineral Research, 2008
- Intravenous Neridronate in Children With Osteogenesis Imperfecta: A Randomized Controlled StudyJournal of Bone and Mineral Research, 2005
- Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among the sclerosing bone disordersJournal of Bone and Mineral Research, 1996
- Osteoclast molecular phenotyping by random cDNA sequencingBone, 1995
- Elevated serum levels of creatine kinase BB in autosomal dominant osteopetrosis Type II — a family studyClinical Genetics, 1992
- Elevated Levels of Creatine Kinase BB Isoenzyme in Three Patients with Adult OsteopetrosisNew England Journal of Medicine, 1989
- Osteogenesis ImperfectaClinical Orthopaedics and Related Research, 1981